Long-term improvement of deceased donor renal allograft survival since 1996: a single transplant center study

Transplantation. 2010 Mar 27;89(6):714-20. doi: 10.1097/TP.0b013e3181c892dd.

Abstract

Background: The rate of acute rejection (AR) has decreased significantly, but whether this is associated with improvement in long-term graft survival is controversial.

Methods: We analyzed 1445 consecutive adult deceased donor kidney transplant recipients from 1985 to 2005, over two periods (1985-1995 vs. 1996-2005) to compare long-term graft survival.

Results: The second period was associated with older donors and recipients and a reduction in AR. A significant increase of 10.1 months at 11 years was seen in death-censored graft survival in 1996 to 2005. For this posttransplant time, graft half-life was 10.8 years in 1985 to 1995, while at this point in the second period 62% of recipients had a functioning graft. The yearly increase in serum creatinine was less pronounced in the latter period (0.05 mg/dL vs. 0.02 mg/dL, P<0.01). No difference was found in patient survival. Cox analysis showed that donor age (HR 1.02, P<0.001), AR (HR 1.72, P<0.001), panel-reactive antibody at transplantation (HR 1.01, P<0.001), and serum creatinine at 1 year (HR 2.01, P<0.001) had a negative impact on graft outcome. By contrast, the use of mycophenolate mofetil was associated with a 24% reduction in graft loss rate (HR 0.76, P<0.05).

Conclusion: Long-term graft survival and renal function have improved in renal transplant recipients since 1996.

Publication types

  • Comparative Study

MeSH terms

  • Acute Disease
  • Adult
  • Female
  • Graft Rejection / etiology
  • Graft Rejection / mortality
  • Graft Rejection / prevention & control*
  • Graft Survival*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kaplan-Meier Estimate
  • Kidney Function Tests
  • Kidney Transplantation* / adverse effects
  • Kidney Transplantation* / mortality
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Spain / epidemiology
  • Time Factors
  • Tissue Donors*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Immunosuppressive Agents